Mizuho Securities analyst Salim Syed has maintained their bullish stance on SNDX stock, giving a Buy rating yesterday. Salim Syed has given ...

Justin Zelin, an analyst from BTIG, reiterated the Buy rating on Mersana Therapeutics (MRSN – Research Report). The associated price ...

Novavax incurred a third-quarter 2024 loss of 76 cents per share, narrower than the Zacks Consensus Estimate of a loss of 87 cents. In the year-ago quarter, the company reported a loss of $1.26 per ...

Issued on behalf of Oncolytics Biotech Inc. "With positive BRACELET-1 results, we have two randomized phase two studies confirming pelareorep's potential in HR+/HER2- metastatic breast cancer,” said ...

Trump Taps Matt Gaetz for Attorney General, a Provocative Move President-elect Trump plans to nominate the Florida congressman, among a flurry of personnel announcements as Republicans neared ...

The interim phase 2 trial results show a good immune response in participants and the therapy is well tolerated to date.

More than 40,000 Gen Z and millennial Bumble users worldwide, including over 2,000 singles in India, participated in the survey.